{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:05:10Z","timestamp":1784005510468,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Occult lung cancer is a rare subtype of non-small cell lung cancer (NSCLC), characterized as an aggressive tumor with a poor prognosis. Its diagnosis relies on biopsy and pathological examinations. A durable complete response (CR) in advanced NSCLC achieved with a chemo-free and radiotherapy-free regimen remains exceedingly rare, particularly in elderly patients with a high tumor burden and unknown PD-L1 status. Here, we report an elderly patient who achieved CR of occult lung squamous cell carcinoma (LUSC) after treatment with a combination of penpulimab and anlotinib as first-line therapy. An 83-year-old man with occult LUSC (cTxN3M0, stage IIIB) presented with a mediastinal mass and multiple mediastinal and bilateral supraclavicular lymph node metastases, confirmed by supraclavicular lymph node examination biopsy. The patient was treated with a combination of penpulimab and anlotinib under close safety monitoring, resulting in a rapid tumor response and complete remission after ten cycles. This remission lasted over two years with no adverse effects observed during or after treatment. The therapy with penpulimab and anlotinib was continued for 26 months before being stopped at the patient\u2019s request. These results suggest that penpulimab plus anlotinib may be a feasible first-line treatment option for elderly patients with advanced LUSC who cannot tolerate or choose to decline standard therapies. Notably, PD-L1 expression was not assessed because the patient refused testing, which prevents definitive conclusions regarding predictive factors associated with the observed response.<\/jats:p>","DOI":"10.3389\/fonc.2026.1841256","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:22:10Z","timestamp":1784002930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoling","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Oncology, Shaoxing People's Hospital, The First Hospital of Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaoxing People's Hospital, The First Hospital of Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaoxing People's Hospital, The First Hospital of Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shaoxing People's Hospital, The First Hospital of Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/jcm11051399","article-title":"Occult non-small cell lung cancer: an underappreciated disease","volume":"11","author":"Cai","year":"2022","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e010674","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728163","article-title":"Lung cancer immunotherapy in 2025: where we stand and what comes next","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.011","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01640-9","article-title":"Penpulimab: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924542","article-title":"Penpulimab, an Fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628124","article-title":"Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102194","article-title":"Penpulimab combined with anlotinib in patients with R\/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase II study","volume":"8","author":"Shi","year":"2023","journal-title":"ESMO Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s188551","article-title":"Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.619010","article-title":"The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer","volume":"10","author":"Zhai","year":"2020","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41392-022-01130-8","article-title":"The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00788-5","article-title":"Immune checkpoint inhibitors for patients aged\u2009\u2265\u200975 years with advanced cancer in first- and second-line settings: a meta-analysis","volume":"37","author":"Landre","year":"2020","journal-title":"Drugs Aging"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31875","article-title":"Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints","volume":"144","author":"Wu","year":"2019","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:22:11Z","timestamp":1784002931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1841256"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1841256","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1841256"}}